Method of treating ischemic disorders

Abstract

A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue.

1 . A method of treating an ischemic disorders in a subject, the method comprising administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue. 
     
     
         2 . The method of  claim 1 , the SDF-1 being administered to cells including SDF-1 receptors that are up-regulated as a result of the ischemic disorder. 
     
     
         3 . The method of  claim 2 , the SDF-1 receptor comprising CXCR4. 
     
     
         4 . The method of  claim 1 , the SDF-1 being administered at amount effect to increase Akt-phosphorylation of the cells. 
     
     
         5 . The method of  claim 1 , the SDF-1 being administered by expressing SDF-1 in the tissue being treated. 
     
     
         6 . The method of  claim 5 , the SDF-1 being expressed from a cell that is biocomaptible with the ischemic tissue being treated. 
     
     
         7 . The method of  claim 5 , the SDF-1 being expressed from a cell of the ischemic tissue or a cell about the periphery of the ischemic tissue. 
     
     
         8 . The method of  claim 7 , the cell expressing the SDF-1 being genetically modified by at least one of a vector, plasmid DNA, electroporation, and nano-particles to express SDF-1. 
     
     
         9 . The method of  claim 1 , further comprising administering MCP-3 to the ischemic tissue at amount effective to recruit stem cells an/or progenitor cells to the ischemic tissue. 
     
     
         10 . The method of  claim 9 , the stem cells comprising autologous and/or syngeneic mesenchymal stem cells. 
     
     
         11 - 16 . (canceled) 
     
     
         17 . The method of  claim 1 , the ischemic disorder comprising at least one of a peripheral vascular disorder, a pulmonary embolus, a venous thrombosis, a myocardial infarction, a transient ischemic attack, unstable angina, cerebral vascular ischemia, a reversible ischemic neurological deficit, ischemic kidney disease, or a stroke disorder. 
     
     
         18 . A method of mitigating apoptosis in cells of a tissue following tissue injury, comprising administering to cells of the tissue an amount of SDF-1 effective to inhibit apoptosis in the cells. 
     
     
         19 . The method of  claim 18 , the cells including SDF-1 receptors that are up-regulated as a result of the ischemic disorder. 
     
     
         20 . The method of  claim 19 , the SDF-1 receptor comprising CXCR4. 
     
     
         21 . The method of  claim 18 , the SDF-1 being administered at amount effect to increase Akt-phosphorylation of the cells. 
     
     
         22 . The method of  claim 18 , the SDF-1 being administered by expressing SDF-1 in the tissue. 
     
     
         23 . The method of  claim 22 , the SDF-1 being expressed from a cell that is biocomaptible with the tissue. 
     
     
         24 . The method of  claim 18 , the SDF-1 being expressed from a cell of the tissue or a cell about the periphery of the tissue. 
     
     
         25 . The method of  claim 23 , the cell expressing the SDF-1 being genetically modified by at least one of a vector, plasmid DNA, electroporation, and nano-particles to express SDF-1. 
     
     
         26 - 49 . (canceled) 
     
     
         50 . A method of mitigating apoptosis of cells or tissue transplanted to a subject being treating, comprising
 administering SDF-1 to cells or tissue to be transplanted to the subject being treated, the cells or tissue expressing an SDF-1 receptor.   
     
     
         51 . The method of  claim 50 , the SDF-1 being administered to the cells or tissue prior to transplantation of the subject being treated. 
     
     
         52 . The method of  claim 50 , the SDF-1 being administered to the cells or tissue during and/or after transplantation of the cells. 
     
     
         53 . The method of  claim 50 , the SDF-1 receptor comprising CXCR4. 
     
     
         54 . The method of  claim 50 , the SDF-1 being administered at amount effect to increase Akt-phosphorylation of the apoptotic cells. 
     
     
         55 . The method of  claim 50 , the cells comprising stem cells and/or progenitor cells expressing SDF-1 receptor.